CCDC26 rs4295627 polymorphism and glioma risk: a meta-analysis.

Several studies have examined the association of CCDC26 rs4295627 polymorphism and glioma risk. However, the results were conflicting. Thus, a meta-analysis was conducted. We searched for relevant studies up to Dec 2014 in both English and Chinese through the PubMed/MEDLINE, EMBASE, the China National Knowledge Infrastructure (CNKI) platforms, WanFang and VIP database. Overall, 14 studies with 17419 cases and 28465 controls were selected for final meta-analysis. CCDC26 rs4295627 polymorphism was significantly associated with an increased risk of glioma (OR = 1.25, 95% CI 1.15-1.36, P < 0.00001). Interestingly, CCDC26 rs4295627 polymorphism might decrease the risk of glioma in Asians (OR = 0.92, 95% CI 0.82-1.03, P = 0.15). However, Caucasians with CCDC26 rs4295627 polymorphism showed an increased risk of glioma (OR = 1.33, 95% CI 1.25-1.46, P < 0.00001). Subgroup analysis was performed by histology. Significant associations were observed among astrocytoma patients (OR = 1.31, 95% CI 1.17-1.47, P < 0.00001) and oligodendroglioma patients (OR = 1.79, 95% CI 1.47-2.17, P < 0.00001). No significant association was found between this polymorphism and glioblastoma risk (OR = 0.11, 95% CI 0.92-1.33, P = 0.28). This meta-analysis suggested that CCDC26 rs4295627 polymorphism was a risk factor for glioma.